Investigational drug · Phase 3
Vebreltinib
Also called: PLB1001
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: May 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
19
Any phase or sponsor naming "Vebreltinib"
First trial start
2018
Oct 8, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vebreltinib", any sponsor or status.
- Phase 215
Conditions studied
As listed on its trial records.
- Non-Small-Cell Lung Cancer
- Glioblastoma
- Non-Small Cell Lung Cancer
- Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Vebreltinib" as an intervention, largest first.
Apollomics Inc.Industry
NCT03175224 · 497 participants (planned) · Start Sep 27, 2017 · Primary completion Mar 30, 2026
Drug: APL-101 Oral Capsules · For: Solid Tumors; Advanced Cancer; Renal Cancer and 15 more
Sites: Los Angeles, California; Tampa, Florida; Boston, Massachusetts · 35 sites in all
- A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-PositivePivotal-lookingRecruiting
Beijing Pearl Biotechnology Limited Liability CompanyIndustry
NCT06930794 · 300 participants (planned) · Start Jul 7, 2025 · Primary completion Feb 2029
Drug: Vebreltinib combined with platinum-based doublet chemotherapy.; platinum-based doublet chemotherapy. · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Guangzhou, China
Tianjin Medical University Second HospitalAcademic, hospital or other
NCT06739395 · 300 participants (planned) · Start Nov 1, 2024 · Primary completion Dec 31, 2026
Drug: Olaparib tablet; Temozolomide capsule and 12 more · For: Solid Tumor; Precision Medicine
Sites: Tianjin, China
- Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailurePivotal-lookingNot yet recruiting
Avistone Biotechnology Co., Ltd.Industry
NCT06970782 · 278 participants (planned) · Start May 15, 2025 · Primary completion Dec 31, 2027
Drug: Vebreltinib; PLB1004 and 1 more · For: Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd.Industry
NCT06343064 · 156 participants (planned) · Start Jun 13, 2023 · Primary completion Dec 31, 2026
Drug: Vebreltinib; PLB1004 · For: Non-Small-Cell Lung Cancer
Sites: Shanghai, China
- A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)Pivotal-lookingRecruiting
Beijing Pearl Biotechnology Limited Liability CompanyIndustry
NCT05989542 · 136 participants (planned) · Start Oct 16, 2023 · Primary completion Sep 30, 2026
Drug: PLB1001 · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.Pivotal-lookingRecruiting
Avistone Biotechnology Co., Ltd.Industry
NCT06574347 · 120 participants (planned) · Start Aug 7, 2024 · Primary completion Oct 31, 2026
Drug: Vebreltinib; Osimertinib and 1 more · For: Non-Small-Cell Lung Cancer
Sites: Guangzhou, China
- A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).Pivotal-lookingActive, not recruiting
Beijing Pearl Biotechnology Limited Liability CompanyIndustry
NCT06105619 · 84 participants · Start Oct 8, 2018 · Primary completion Apr 1, 2023
Drug: PLB1001; Temozolomide and 1 more · For: Glioblastoma
Sites: Beijing, China
Huashan HospitalAcademic, hospital or other
NCT06780592 · 60 participants (planned) · Start Jan 13, 2025 · Primary completion Dec 31, 2025
Drug: Vebreltinib + Temozolomide; Temozolomide · For: Glioblastoma
- A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian ParticipantsStatus unknown
Apollomics Inc.Industry
NCT05367388 · 48 participants (planned) · Start May 20, 2022 · Primary completion Nov 2022
Drug: APL-101; PLB-1001 · For: Bioequivalence
Sites: Auckland, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
- Structural analysis and crystallography-guided pharmacophore elucidation of capmatinib analogues as selective c-MET targeting anticancer agents.
Valipour M · Eur J Med Chem 2027
- Severe cutaneous adverse reaction to aumolertinib plus vebreltinib in an EGFR-mutant NSCLC patient: a case report.
Zhang Y, Zhang L, Ding J · Front Oncol 2026
- Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report.
Hang Y, Bai L, Hsu H, et al. · Oncologist 2026
- Unravelling the human disposition of [14C]-vebreltinib: Faecal recovery of parent drug and a major circulating metabolite defines its mass balance profile.
Li L, Xue W, Yin H, et al. · Br J Clin Pharmacol 2026
- VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.
Jiang Y, Lin N, Huang X, et al. · Future Oncol 2026
- Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants.
Chen J, Wu J, Song Y, et al. · Clin Transl Sci 2026
Also in development for Non-Small-Cell Lung Cancer
- AndamertinibPLB1004Phase 38 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- CAB-AXL-ADCBA3011Phase 22 trials
BioAtla, Inc. · Non-Small-Cell Lung Cancer, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.